News
Uplizna is first drug FDA-cleared for rare disease IgG4-RD
Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.
Friday 25 July 2025
